Literature DB >> 12443807

Scoring of treatment-related late effects in prostate cancer.

Jacqueline E Livsey1, Jacqueline Routledge, Meriel Burns, Rick Swindell, Susan E Davidson, Richard A Cowan, John P Logue, James P Wylie.   

Abstract

BACKGROUND AND
PURPOSE: To assess the correlation between different general and organ specific quality of life and morbidity scoring methods in a cohort of men treated with radical radiotherapy for prostate cancer.
MATERIALS AND METHODS: Men who had been treated with radical radiotherapy (50 Gy in 16 fractions over 21 days) for localized prostate cancer more than 3 years previously and who had no evidence of recurrent disease were invited to take part in the study. A total of 101 of 135 invited patients agreed and completed LENT/SOMA, UCLA Prostate Cancer Index, and 36 item RAND Health survey questionnaires.
RESULTS: The patients had comparable results with other published series with respect to the UCLA and SF-36 indices. There was significant correlation between the corresponding parts of the UCLA and LENT/SOMA scales (P<0.0005). However, for the same symptoms, a patient tended to score lower (worse) on the UCLA scale in comparison to LENT/SOMA. The relationship between the average LENT/SOMA score and maximum score was also not straightforward with each set of data revealing different information.
CONCLUSIONS: The LENT/SOMA questions were, in the main, more wide-ranging and informative than the UCLA index. It is helpful to give both the overall and maximum LENT/SOMA scores to most efficiently use all of the data. There may need to be a further LENT/SOMA question to allow both symptoms of tenesmus and faecal urgency to be fully addressed.

Entities:  

Mesh:

Year:  2002        PMID: 12443807     DOI: 10.1016/s0167-8140(02)00286-4

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

Review 1.  Technological advances in radiation therapy for prostate cancer.

Authors:  Mehee Choi; Arthur Y Hung
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

2.  Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists.

Authors:  Minh-Phuong Huynh-Le; Zhe Zhang; Phuoc T Tran; Theodore L DeWeese; Daniel Y Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-13       Impact factor: 7.038

3.  Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy.

Authors:  Richard Crevenna; Georg Zettinig; Mohammad Keilani; Martin Posch; Manuela Schmidinger; Christian Pirich; Martin Nuhr; Michael Wolzt; Michael Quittan; Veronika Fialka-Moser; Robert Dudczak
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

4.  A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy.

Authors:  F A Olopade; A Norman; P Blake; D P Dearnaley; K J Harrington; V Khoo; D Tait; C Hackett; H J N Andreyev
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

5.  Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).

Authors:  Isabel Syndikus; Rachel C Morgan; Matthew R Sydes; John D Graham; David P Dearnaley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

6.  Dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity.

Authors:  David Thomson; Sophie Merrick; Ric Swindell; Joanna Coote; Kay Kelly; Julie Stratford; James Wylie; Richard Cowan; Tony Elliott; John Logue; Ananya Choudhury; Jacqueline Livsey
Journal:  Prostate Cancer       Date:  2012-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.